Sign In
Buy MNMD
$20.69
+0 (+0%)
At Close: Jun 18, 2026
MindMed Collaborates with Nextage Therapeutics for Brain Targeting Liposome System
12:06pm, Monday, 24'th May 2021
MindMed (NASDAQ: MNMD) and Israel-listed Nextage Therapeutics have entered into an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates. The
7 Cheap Stocks to Buy Now Under $10
11:30am, Monday, 24'th May 2021
While no one likes to see red ink on their portfolio, a key benefit is that you now have more choices regarding cheap stocks to buy. The post 7 Cheap Stocks to Buy Now Under $10 appeared first on Inve
MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System
07:30am, Monday, 24'th May 2021
NEW YORK, May 24, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage psychedelic medicine company, and Nextage Therapeutics (TASE: NXTG), an Israeli innovative d
Why MindMed stock doubled in one day - JR Rahn
11:35am, Friday, 21'st May 2021
(Kitco News) - The day MindMed listed on the NASDAQ in late April, the share price more than doubled in one day from $2.73 a share to $5.80.
The Jury's Still Out on Psychedelics Play MindMed Stock
03:10pm, Thursday, 20'th May 2021
It has a shot of finding success. Yet, said success remains many years away.
MindMed To Conduct The First Modern Research On Mescaline In Switzerland
02:25pm, Thursday, 20'th May 2021
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), announced Thursday that it had obtained authorization from the local Swiss ethics committee to conduct the first clinical trial on mescaline. What Hap
MindMed Announces the Approval of Mescaline Study
07:30am, Thursday, 20'th May 2021
BASEL, Switzerland, May 20, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading clinical stage psychedelic medicine company, announced today the approval by the local Swiss e
The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing
06:30pm, Tuesday, 18'th May 2021
NEW YORK, May 18, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) ("MindMed" or the "Company"), a leading clinical stage psychedelic medicine company, today an
Strong Cash Balance Should Provide a Foundation for MindMed Stock
10:18am, Tuesday, 18'th May 2021
Now that it has joined the Nasdaq Exchange, MNMD stock will have its ups and downs but firm financials should instill shareholder confidence. The post Strong Cash Balance Should Provide a Foundation f
MindMed Stock Moves Higher After Finalizing Generalized Anxiety Disorder As Initial Indication For LSD Trial
10:00am, Monday, 17'th May 2021
After receiving Type C Meeting Responses from the FDA, MindMed (NASDAQ: MNMD) has selected Generalized Anxiety Disorder as an initial indication for its Project Lucy, evaluating LSD. The company is o
Penny Stocks On Robinhood For You May 2021 Watch List
04:31pm, Sunday, 16'th May 2021
Robinhood penny stocks to watch for the next half of May The post Penny Stocks On Robinhood For You May 2021 Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks
MindMed Announces Appointment of Dr. Sarah Y. Vinson as Additional Director
07:49am, Friday, 14'th May 2021
NEW YORK, May 14, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) ("MindMed" or the "Company") is pleased to announce that it has appointed Dr. Sarah Y. Vinso
MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline
07:32am, Friday, 14'th May 2021
NEW YORK, May 14, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed'' or the "Company") (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, has announced i
EXCLUSIVE: MindMed CEO Talks Mission To 'Discover, Develop And Deploy' Psychedelics
02:46pm, Thursday, 13'th May 2021
Mind Medicine Inc (NASDAQ: MNMD) was started to address mental wellness, CEO and co-founder J.R. Rahn told Benzinga's Global Small Cap Conference Thursday.
MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development
07:30am, Thursday, 13'th May 2021
NEW YORK, May 13, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic-inspired medicine company has appointed Peter Mack PhD as Vice President of Pharmaceutical D
